AI-generated summary
This single-center retrospective study of 25 patients who had autologous stem cell transplants assessed a photobiomodulation device for preventing and treating oral mucositis. The authors report no device-related adverse events, with 76% of patients having grade 0 or 1 mucositis, and describe the efficacy as promising. The study was retrospective and single-center, and the abstract describes the results only in descriptive terms.
- Participants
- 25
- Who or what was studied
- Adults with hematological malignancies who underwent autologous hematopoietic stem cell transplantation between November 2020 and October 2021 (median age 58 years; 56% male)
- Limits stated in the abstract
- Single-center retrospective design with a small sample of 25 patients and no control group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Energy density (fluence)
- 3 J/cm2, 6 J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Oral mucositis, GRADE, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.